RetaCalc
Protocol library
SingleNot ApprovedMixedVery Low confidenceSourced

CJC-1295 no DAC

A short-acting GHRH analogue name that does not map to the long-acting DAC-linked CJC-1295 used in the best-known human trials.

Evidence context, not a personal protocol

Quantities below reproduce their stated source context—label, human study, laboratory work or educational guide. They do not assess suitability, product equivalence or individual risk.

Dosage and protocol evidence

Each card states what the quantities are based on. A third-party or animal schedule is not a validated human dose.

Community GuideSubcutaneous in guideDaily
Third-party educational no-DAC schedule

100 mcg daily in weeks 1-2, 150 mcg in weeks 3-4, 200 mcg in weeks 5-6 and 250-300 mcg in weeks 7-12

No matched human no-DAC dose-finding trial validates this schedule. The published CJC-1295 study used the pharmacologically different long-acting DAC-linked molecule.

View source
Evidence Gap
Healthy adults in a long-acting CJC-1295 trial

The human study evaluated DAC-linked CJC-1295, not the no-DAC compound named on this page

This is an evidence-boundary card rather than a transferable dose. Its amounts and intervals must not be imported into no-DAC products.

View source

Evidence summary

A short-acting GHRH analogue name that does not map to the long-acting DAC-linked CJC-1295 used in the best-known human trials.

Protocol basis

The protocol basis is a formulation mismatch. The human study proves that DAC-linked CJC-1295 affects GH and IGF-1, but it cannot validate a no-DAC schedule.

What remains uncertain

The identity behind retail no-DAC naming, human pharmacokinetics, validated intervals and clinical outcomes remain uncertain.

Warnings and contraindications

Published CJC-1295 human studies used a long-acting albumin-binding DAC formulation.
Long-acting study quantities and intervals cannot be applied to no-DAC products.
Growth-hormone and IGF-1 manipulation requires specialist endocrine context.